Li et al153recently found that ADH4 expression in HCC correlated negatively with the infiltration of immune cells (e.g., CD19+ B cells, CD68+ macrophages, and CD4+ T cells) and the expression of immune checkpoint proteins (e.g., cytotoxic T lymphocyte–associated antigen-4, programmed cell death protein 1, lymphocyte activation gene-3, and vascular endothelial growth factor B), suggesting that ADH4 is a potential target for immunotherapeutic intervention for HCC. This evidence concerns the gene VEGFB and hepatocellular carcinoma.